(ANPC) – Press Releases
-
Fresh2 Group Ltd. Announces Acquisition of Cross-Border Food E-Commerce Platform Youfood Group Inc.
-
Appointment of New Independent Director
-
Fresh2 Group Launches Roxe Restaurant Robots, Spearheading Smart Automation in Culinary Services
-
Fresh2 Group Ltd. Completes Acquisition of SpeedIn INC, a Delivery Service Provider
-
Fresh2 Group Ltd. Appoints New Chief Strategy Officer to Drive Advancement and Execution of Long-Term Growth Strategy
-
Fresh2 Group Ltd. (FRES) Rings the Nasdaq Stock Market Opening Bell, Driving the Online Transformation of the Restaurant Industry
-
Fresh2 Group Ltd. Regains Compliance with Nasdaq Listing Requirements
-
Fresh2 Group Ltd. Announces US$4.4 Million Private Placement
-
Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'
-
Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022
-
Fresh2 Reports Fiscal Year 2022 Annual Financial Results
-
Fresh2 Reports First Quarter of Fiscal Year 2023 Financial Results
-
Univest Securities, LLC Announces Closing of $3.0 Million Registered Direct Offering for its Client AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC)
-
AnPac Bio-Medical Science Announces Closing of $3.0 Million Registered Direct Offering
-
AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.
-
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering
-
AnPac Bio-Medical Science Announces Pricing of $3.0 Million Registered Direct Offering
-
AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023
-
AnPac Bio Announces Receipt of the First Payment from a Malaysia Customer On a Signed US$1.5 Million Cancer Detection Equipment Purchase Contract
-
AnPac Bio-Medical Science Announces US$5 Million Private Placement
-
AnPac Bio Announces Positive Results from its Multi-Year and Multi-Cancer Test Follow-Up Study
-
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
-
AnPac Bio-Medical Science Enters into Definitive Agreement to Make Another Acquisition to Significantly Expand Scope of Business in the U.S.
-
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
-
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
-
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing
-
AnPac Bio Reports 48.8% Decrease in Net Loss in First Half of 2022
-
AnPac Announces the Plan of US$5,000,000 Private Placement
-
AnPac Announces the Plan of US$5,000,000 Private Placement
-
AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market
-
AnPac Announces Strategic Initiative to Establish A Wholly-Owned Subsidiary for US Food Market
-
AnPac Announces Regaining Compliance with Nasdaq Listing Requirement
-
AnPac Announces Regaining Compliance with Nasdaq Listing Requirement
-
AnPac Bio Announces Changes to the Board of Directors
-
AnPac Bio Announces Changes to the Board of Directors
-
AnPac Bio Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting $1 Bid Price Compliance Rule On or Before Nov. 23, 2022
-
AnPac Bio Announces Plan to Implement ADS Ratio Change
-
AnPac Bio Announces Plan to Implement ADS Ratio Change
-
AnPac Bio Announces Board and Management Changes
-
AnPac Bio Announces Board and Management Changes
-
AnPac Bio and New Investor Group Sign Equity Investment Totaling $3.67 Million
-
AnPac Bio Appeals NASDAQ Delisting Notice; Hearing Granted and Scheduled for October 20, 2022
-
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Appeal
-
AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer
-
AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees
-
AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market
-
AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022
-
AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022
-
AnPac Bio Reports Fiscal Year 2021 Annual Financial Results
-
AnPac Bio Reports Fiscal Year 2021 Annual Financial Results
Back to ANPC Stock Lookup